Golimumab is a human monoclonal antibody administered at the time per month by subcutaneous injection. While it's got an identical security and efficacy profile to other TNFi, golimumab is considerably less successful than other TNFi in people who have unsuccessful a number of biological therapies. The PrismRA final result helps https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/